A pancreaticus lipidakkumuláció–amelyet egyre gyakrabban NAFPD (non-alcoholic fatty
pancreas disease) néven említenek az angol nyelvű szakirodalomban–az elmúlt néhány …

Цель. Анализ актуальных тенденций зарубежной практики в области разработки и
регистрации лекарственных препаратов. Материалы и методы. При поиске материала …

Pharmaceutical interventions play a vital role in managing various conditions, including
weight-related issues such as obesity. In this context, lifestyle changes are often challenging …

Resumo Tirzepatide, developed by Eli Lilly and Company, is an innovative dual GIP and
GLP-1 agonist administered on a weekly basis. This compound has proven to be highly …

Diabetes mellitus (DM) is a metabolic condition that raises blood glucose levels
(hyperglycemia) without insulin or insulin receptor defects. Insulin is a peptide hormone the …

Results. The discovery and development of drugs are among the most crucial scientific
processes in healthcare. Developing a new drug is a highly intricate, expensive, and time …

Type 2 diabetes mellitus is a complex metabolic disease with complex derangements of
metabolic pathways that are involved in the glucose metabolism in different organs: the liver …

The biggest receptor family in the genome, G-protein coupled receptors (GPCRs), are of
tremendous interest for the development of innovative medications for a wide range of …

Glucagon-like peptide-1 (GLP-1), an incretin secreted by intestinal L cells, has become a
critical target for the treatment of type 2 diabetes because of its physiological effects of …

Background Obesity became a recent pandemic, especially, during the Corona Virus
Pandemic of 2019 (COVID-19) lockdown. Therefore, people started to adopt effortless …